254.54MMarket Cap-5285P/E (TTM)
1.890High1.820Low18.98KVolume1.890Open1.900Pre Close35.00KTurnover0.02%Turnover RatioLossP/E (Static)137.59MShares2.34052wk High1.74P/B163.86MFloat Cap0.76552wk Low--Dividend TTM88.57MShs Float8.800Historical High--Div YieldTTM3.68%Amplitude0.765Historical Low1.844Avg Price1Lot Size
Compass Therapeutics Stock Forum
NEWS
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
Compass Therapeutics dosed the first patient in the Phase 1 trial of CTX-8371, a novel dual checkpoint blocker targeting PD-1 and PD-L1 in patients with solid tumors. The study aims to evaluate the drug's efficacy in patients who failed prior checkpoint blocker treatments.
• $Livent (LTHM.US)$ +22.58% (it posted better-than-expected quarterly earnings and raised its 2022 revenue forecast)
• $Super Micro Computer (SMCI.US)$ +11.01% (earnings reports)
• $Oatly Group AB (OTLY.US)$ +8.31% (earnings reports)
• $BlueLinx Holdings (BXC.US)$ +9.7% (increases share repurchase authorization to $100 mln; enters into $60 mln accelerated repurchase agreement)
• $Starbucks (SBUX.US)$ +7.18% (matched estimates wi...
No comment yet